Article Text

Download PDFPDF

Reactions to electronic nicotine delivery system (ENDS) prevention messages: results from qualitative research used to inform FDA’s first youth ENDS prevention campaign
  1. Maria L Roditis1,
  2. Atanaska Dineva1,
  3. Alexandria Smith1,
  4. Matthew Walker1,
  5. Janine Delahanty1,
  6. Emily D'lorio1,
  7. Kristen D Holtz2
  1. 1Office of Health Communication and Education, Center for Tobacco Products, US Food and Drug Administration, Silver Spring, Maryland, USA
  2. 2KDH Research and Communication, Atlanta, Georgia, USA
  1. Correspondence to Dr Maria L Roditis, Office of Health Communication and Education, Center for Tobacco Products, US Food and Drug Administration, Silver Spring, MD 20903, USA; maria.roditis{at}fda.hhs.gov

Footnotes

  • Contributors All authors helped in the conceptualisation, writing and editing of the paper. MLR, AD and AS did the analysis of the results. MLR led the writing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer This publication represents the views of the author(s) and does not represent FDA/CTP position or policy.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The FDA IRB reviewed and approved the protocol for this study (ID No 17-083CTP).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors helped in the conceptualisation, writing and editing of the paper. MLR, AD and AS did the analysis of the results. MLR led the writing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer This publication represents the views of the author(s) and does not represent FDA/CTP position or policy.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The FDA IRB reviewed and approved the protocol for this study (ID No 17-083CTP).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.